The study presented here aimed to evaluate the prevalence, dynamics and clinical impact of BCR::ABL1 independent gene mutations in chronic phase CML patients treated with nilotinib in an ongoing prospective clinical trial. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.